Canadian Journal of Anesthesia, Vol 39, 353-365, Copyright © 1992 by Canadian Anesthesiologists' Society

ARTICLES

Natural and synthetic antifibrinolytics in cardiac surgery

JF Hardy and J Desroches
Department of Anaesthesia, University of Montreal, Quebec.

In an effort to reduce morbidity associated with transfusion of blood products, the use of antifibrinolytics to decrease bleeding and transfusions after cardiopulmonary bypass (CPB) is receiving widespread attention. The predominant haemostatic defect induced by CPB and, therefore, the mechanisms by which natural (aprotinin) or synthetic antifibrinolytics (sigma-amino-caproic acid, tranexamic acid) exert their effects have been difficult to define. Nonetheless, all three substances appear to be effective in the treatment or in the prevention of excessive bleeding associated with cardiac surgery. However, the administration of these drugs should not attempt to replace meticulous surgical and anaesthetic care. In particular, the importance of an appropriate transfusion practice cannot be overemphasized. The efficient use of these, sometimes expensive, drugs must take into account not only the initial cost, but also the short- and long-term economic consequences for the health care provider of using, or not using, a given medication. Unfortunately, the comprehensive data on which authoritative conclusions may be reached are not yet available. Pending availability of these data, the present use of antifibrinolytics at the Montreal Heart Institute is the following: (1) patients undergoing elective primary myocardial revascularization or valve surgery do not receive prophylactic antifibrinolytics; (2) patients undergoing repeat myocardial revascularization, repeat valve surgery, or primary or repeat combined procedures, receive prophylactic sigma-aminocaproic acid; (3) sigma-aminocaproic acid may be used to treat excessive chest drainage in the postoperative period; (4) the prophylactic and the therapeutic uses of low doses of aprotinin are currently under investigation.

This article has been cited by other articles:

				S. Ulker, P. P McKeown, and U. Bayraktutan Aprotinin impairs coronary endothelial function and down-regulates endothelial NOS in rat coronary microvascular endothelial cells Cardiovasc Res, September 1, 2002; 55(4): 830 - 837. [Abstract] [Full Text] [PDF]

				D. T. Neilipovitz, K. Murto, L. Hall, N. J. Barrowman, and W. M. Splinter A Randomized Trial of Tranexamic Acid to Reduce Blood Transfusion for Scoliosis Surgery Anesth. Analg., July 1, 2001; 93(1): 82 - 87. [Abstract] [Full Text] [PDF]

				S. Ulker, M. G. Cinar, U. Bayraktutan, and A. Evinc Aprotinin impairs endothelium-dependent relaxation in rat aorta and inhibits nitric oxide release from rat coronary endothelial cells Cardiovasc Res, June 1, 2001; 50(3): 589 - 596. [Abstract] [Full Text] [PDF]

				C. J. East, F. Clements, J. Mathew, and T. F. Slaughter Antiphospholipid Syndrome and Cardiac Surgery: Management of Anticoagulation in Two Patients Anesth. Analg., May 1, 2000; 90(5): 1098 - 1101. [Full Text] [PDF]

				B. I. Wong, R. F. McLean, S. E. Fremes, K. A. Deemar, E. M. Harrington, G. T. Christakis, and B. S. Goldman Aprotinin and tranexamic acid for high transfusion risk cardiac surgery Ann. Thorac. Surg., March 1, 2000; 69(3): 808 - 816. [Abstract] [Full Text] [PDF]

				P. S. Myles Aspects of Anesthesia for Lung Transplantation Seminars in Cardiothoracic and Vascular Anesthesia, July 1, 1998; 2(2): 140 - 154. [Abstract] [PDF]

				M. A. Forgie, P. S. Wells, A. Laupacis, D. Fergusson, and for the International Study of Perioperative Trans Preoperative Autologous Donation Decreases Allogeneic Transfusion but Increases Exposure to All Red Blood Cell Transfusion: Results of a Meta-analysis Arch Intern Med, March 23, 1998; 158(6): 610 - 616. [Abstract] [Full Text] [PDF]

				T. J. Vander Salm, S. Kaur, R. A. Lancey, O. N. Okike, A. T. Pezzella, R. F. Stahl, L. Leone, J.-M. Li, C. R. Valeri, and A. D. Michelson REDUCTION OF BLEEDING AFTER HEART OPERATIONS THROUGH THE PROPHYLACTIC USE OF EPSILON-AMINOCAPROIC ACID J. Thorac. Cardiovasc. Surg., October 1, 1996; 112(4): 1098 - 1107. [Abstract] [Full Text]

				R. Gitter, P. Alivizatos, J. Capehart, M. Ramsay, and G. K. Jett BRIEF COMMUNICATIONSAPROTININ AND AORTIC CANNULA THROMBOSIS J. Thorac. Cardiovasc. Surg., August 1, 1996; 112(2): 537 - 538. [Full Text]

				Z.'e. Zonis, M. Seear, C. Reichert, S. Sett, and C. Allen THE EFFECT OF PREOPERATIVE TRANEXAMIC ACID ON BLOOD LOSS AFTER CARDIAC OPERATIONS IN CHILDREN J. Thorac. Cardiovasc. Surg., May 1, 1996; 111(5): 982 - 987. [Abstract] [Full Text]

				D. Katsaros, M. Petricevic, N. J. Snow, D. D. Woodhall, and R. Van Bergen Tranexamic Acid Reduces Postbypass Blood Use: A Double-Blinded, Prospective, Randomized Study of 210 Patients Ann. Thorac. Surg., April 1, 1996; 61(4): 1131 - 1135. [Abstract] [Full Text]

				R. M Montesano, P. A Gustafson, D. A Palanzo, N. J Manley, and F. S Sadr The effect of low-dose epsilon-aminocaproic acid on patients following coronary artery bypass surgery Perfusion, January 1, 1996; 11(1): 53 - 56. [Abstract] [PDF]

				G. E. Hill, A. Alonso, J. R. Spurzem, A. H. Stammers, and R. A. Robbins APROTININ AND METHYLPREDNISOLONE EQUALLY BLUNT CARDIOPULMONARY BYPASS-INDUCED INFLAMMATION IN HUMANS J. Thorac. Cardiovasc. Surg., December 1, 1995; 110(6): 1658 - 1662. [Abstract] [Full Text]

				B. Blauhut, W. Harringer, P. Bettelheim, J. E. Doran, P. Spath, and P. Lundsgaard-Hansen Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass J. Thorac. Cardiovasc. Surg., December 1, 1994; 108(6): 1083 - 1091. [Abstract] [Full Text]

				H. I. Saba, G. A. Morelli, and L. A. Logrono Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia with Aminocaproic Acid N. Engl. J. Med., June 23, 1994; 330(25): 1789 - 1790. [Full Text]